HRS-9531

药时代寻找对创新药Biotech 实实在在感兴趣且资金充沛的投资公司 请立即联系药时代BD团队（BD@drugtimes.cn）！ 正文共：800字  预计阅读时间：2分钟 2025年10月14日 ，Kailera Therapeutics（恒瑞Newco公司）今日宣布完成6亿美元B轮融资。 2024年5月，恒瑞医药宣布授予Hercules CM NewCo（Kailera前身）在除大中华区以外的全球范围内开发、生产和商业化三款GLP-1产品（HRS-7535、HRS9531和HRS-4729）的独家权益。 本轮投资由新晋投资方贝恩资本私募股权基金（Bain Capital Private Equity）领投，新老投资者共同参与，融资资金将专项用于推进公司差异化晚期肥胖治疗药物管线，特别是加速核心候选药物KAI-9531（即HRS9531）的全球III期临床计划。 本轮新晋投资机构阵容豪华，包括 Adage Capital Management LP、加拿大养老金计划投资委员会 （CPP Investments）、Invus、Janus Henderson investors、Perseverance Capital、卡塔尔投资局 （QIA）、Royalty Pharma、Surveyor Capital、T. Rowe Price Associates，以及一只未披露的大型共同基金。 公司原有投资方Atlas Venture、贝恩资本生命科学基金、RTW投资和Sirona Capital亦继续追加投资。 目前，Kailera已顺利完成FDA的II期临床总结会议，计划于2025年底前启动全球III期临床试验。该试验将包含三项研究：针对伴发疾病的肥胖或超重成人患者（含2型糖尿病患者及非糖尿病患者）的两项试验，以及针对BMI≥35重度肥胖人群的专项研究。 此外，融资收益还将用于推进KAI-7535（HRS-7535）与KAI-4729（HRS-4729）的国际化开发。 图片来源：即梦AI 全球首款！TROP2 ADC又一适应症获批 2025-10-13 2.5亿美元即将到账！百利天恒与BMS合作达到里程碑 2025-10-12 又一MNC终止细胞治疗研发 2025-10-11 版权声明/免责声明 本文为编译文章。 本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。 文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。 如有任何问题，请与我们联系。 衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

Kailera Therapeutics, one of the most closely-watched private obesity biotechs, has raised a $600 million Series B to begin Phase 3 trials by year’s end. The Tuesday morning financing is the same size as Isomorphic Labs’ capital haul in March , tying Kailera with the Alphabet AI drug discovery unit for the largest biotech fundraise of the year. Kailera jumped into the obesity biotech landscape last year with assets licensed from Chinese drug development powerhouse Hengrui Pharma. It snagged a $400 million launch round last year. Since then, the obesity drug R&D race has further amplified, with Eli Lilly pulling ahead of Novo Nordisk, Pfizer making a splash with an acquisition of Metsera and AbbVie joining the field. Waltham, MA-based Kailera said it will use the new funds to start two global Phase 3 trials of KAI-9531, the injectable GLP-1/GIP receptor agonist it in-licensed from Hengrui this year. The trials will include adults with obesity or overweight with and without type 2 diabetes. Kailera is also planning a trial in adults with a BMI of 35 or higher, who are classed as having obesity. In an interview, Kailera CEO Ron Renaud said the company anticipates the Phase 3 trials will “enroll very, very quickly.” “Obesity studies are quite popular right now, and from everything that we’ve seen and heard, they’re very attractive for patients,” Renaud told Endpoints News . In the same interview, Andrew Kaplan said KAI-9531 is a “sweet spot of safety, efficacy and tolerability.” Kaplan is joining the Kailera board and is partner at Bain Capital Private Equity, which led the new round. Funding will also go toward an oral small-molecule GLP-1 receptor agonist called KAI-7535; an injectable GLP-1/GIP/glucagon receptor tri-agonist dubbed KAI-4729; and a once-daily tablet version of KAI-9531. Kailera also has rights to new formulations of products it licensed from Hengrui. Further, the company has the right of first refusal for certain assets in Hengrui’s metabolic disease pipeline. “As we think about what our portfolio looks like today, if there’s a need — a big if — to fortify it, we can have those conversations with our colleagues at Hengrui and exercise those option rights if we need to,” Renaud said. Adage Capital Management, Canada Pension Plan Investment Board, Invus, Royalty Pharma, Qatar Investment Authority and other new and existing investors participated. Kailera, which also has an office in San Diego, has grown to about 130 to 140 employees, Renaud said. Editor’s note: This story was updated to include details from an interview with Ron Renaud and Andrew Kaplan and to correct Kaplan’s title.